Cue Biopharma director Daniel Camardo files Form 3

Cue Biopharma, Inc. filed an initial insider ownership report for Daniel A. Camardo, who is identified as a director of the company.

Rhea-AI Filing Summary

Cue Biopharma, Inc. filed an initial insider ownership report for Daniel A. Camardo, who is identified as a director of the company. This Form 3 data shows no reported buy, sell, or other share transactions and no derivative positions for him in this filing snapshot.

Key Terms

Form 3, director, ten percent owner

3 terms

Form 3 regulatory

"filed an initial insider ownership report for Daniel A. Camardo"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

director financial

"Daniel A. Camardo, who is identified as a director of the company"

ten percent owner financial

"the ten percent owner indicator is set to zero in the provided data"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Daniel A. Camardo’s Form 3 mean for Cue Biopharma (CUE)?

The Form 3 identifies Daniel A. Camardo as a director of Cue Biopharma. It is an initial insider ownership report and, in this data snapshot, lists no share transactions or derivative positions for him.

Does Daniel A. Camardo report any stock transactions in this Cue Biopharma (CUE) Form 3?

No. The Form 3 data for Daniel A. Camardo shows no buy, sell, or other transactions. Transaction counts and share amounts are all zero in the provided summary fields.

Is Daniel A. Camardo a 10% owner of Cue Biopharma (CUE) according to this Form 3?

No. The Form 3 classification flags Daniel A. Camardo as a director but not a ten percent owner. The ten percent owner indicator is set to zero in the provided data.

Are there any derivative securities reported for Daniel A. Camardo in Cue Biopharma’s Form 3?

No derivative securities are listed. The derivativeSummary is empty, and derivative-related transaction counts, such as exercises, are all zero in the transaction summary fields.

Does the Form 3 for Daniel A. Camardo show any gifts or tax-withholding transactions in CUE shares?

No. Gift and tax-withholding fields in the transactionSummary are zero, indicating no gifts, tax-withholding dispositions, or restructuring entries for Cue Biopharma shares in this filing snapshot.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:23 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Camardo Daniel A.

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/30/2026

3. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Michael Meluzio, Attorney-in-Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)